Skip to Content

    The number of adults living with diabetes has almost doubled globally since 1980, with the World Health Organization estimating that 422 million adults were living with the disease in 2014. To help address the crisis, in 2015, Dexcom, a medical device company specializing in the development of continuous glucose monitoring (CGM) systems for diabetics, released the G5 Mobile CGM System, the first to enable real-time tracking of glucose levels for adults and even young children. And Dexcom is partnering with Google’s life ­sciences arm, Verily, to launch a coproduced miniature CGM system next year. Dexcom’s stock price plunged in late September, however, after news that pharma giant Abbott Laboratories had received FDA approval for a rival glucose monitoring system that won’t require a pinprick.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score2.6
    Sector
    Health Care
    Industry
    Medical Products and Equipment
    CEO
    Kevin R. Sayer
    Websitehttp://www.dexcom.com
    Employees1,900
    HQ Location
    San Diego, Calif.
    Revenues ($M) (Past 12 Months)$633
    Profits ($M) (Past 12 Months)$-65
    Market Value as of Oct. 9, 2017 ($M)$4,093